Connect with us

Great-West Lifeco reports second quarter 2022 results

Great-West Lifeco reports second quarter 2022 results
Canada NewsWire
WINNIPEG, MB, Aug. 3, 2022

TSX:GWO
This release should be read in conjunction with Great-West Lifeco’s Quarterly Report to Shareholders for the period ended June 30, 2022, availa…

Published

on

Great-West Lifeco reports second quarter 2022 results

Canada NewsWire

TSX:GWO

This release should be read in conjunction with Great-West Lifeco's Quarterly Report to Shareholders for the period ended June 30, 2022, available on greatwestlifeco.com. The Quarterly Report to Shareholders includes the Company's interim Management's Discussion & Analysis (MD&A) and condensed consolidated interim unaudited Financial Statements for the period, prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board unless otherwise noted. Additional information relating to Great-West Lifeco is available on sedar.com. Readers are referred to the cautionary notes regarding Forward-Looking Information and Non-GAAP Financial Measures and Ratios at the end of this release. All figures are expressed in millions of Canadian dollars, unless otherwise noted.

WINNIPEG, MB, Aug. 3, 2022 /CNW/ - Great-West Lifeco Inc. (Lifeco or the Company) today announced its second quarter 2022 results. Net earnings of $735 million were down by 6% and base earnings1 of $830 million were slightly up compared to the same period in 2021.

"Against the backdrop of falling equity markets and elevated inflation, the Company's well diversified and resilient business portfolio delivered solid results," said Paul Mahon, President and CEO of Great-West Lifeco. "Strong insurance and investment results offset the dampening effect of equity markets on wealth and asset management businesses. We are pleased with the progress we are making on our strategic priorities including the recent close of Empower's acquisition of the full-service retirement business of Prudential Financial Inc. The integration of this and our other acquired businesses in the U.S. are on track and we remain confident in the outlook for Empower and our value creation objectives for the business."

Key Financial Highlights


Base earnings

Net earnings

Common Shareholders

Q2 2022

Q2 2021

Q2 2022

Q2 2021

Segment earnings





Canada

$                296

$               293

$            301

$               288

United States

143

190

29

150

Europe

208

184

229

185

Capital and Risk Solutions

174

150

167

152

Lifeco Corporate

9

9

9

9

Total earnings

$                830

$               826

$            735

$               784

EPS2

$               0.89

$              0.89

$           0.79

$              0.84

Return on equity2,3

14.5 %

13.9 %

13.7 %

15.0 %

 

In the second quarter of 2022, equity markets in the regions where the Company operates exhibited heightened volatility and ended 5% to 16% lower than March 31, 2022 levels. Interest rates increased 80-105bps in response to elevated, broad based levels of inflation which are impacting business and consumer confidence. In addition, the Canadian dollar strengthened notably against the British pound and the Euro, although weakened somewhat against the U.S. dollar.

Base earnings per share (EPS) for the second quarter of 2022 of $0.89 was consistent with $0.89 a year ago. This reflected strong insurance and investment results in all geographies which more than offset reduced net fee income from wealth management businesses and negative currency movement impacts. Base earnings grew year-over-year in the Canada, Europe and Capital and Risk Solutions segments. The U.S. segment base earnings were the most impacted by market conditions resulting in lower year-over-year base earnings notwithstanding the addition of Prudential business related base earnings of $45 million (US$35 million).

Reported net EPS for the second quarter of 2022 was $0.79, down from $0.84 a year ago, primarily due to higher acquisition related costs largely from the Prudential acquisition. Also, the second quarter of 2021 included a revaluation of deferred taxes resulting in an increase in taxes in the Europe segment; there was no revaluation in 2022.

Return on equity of 13.7% and base return on equity of 14.5% in the second quarter of 2022 continued to be solid in light of the macroeconomic challenges and remain within our target range.

___________________

1

Base earnings is a non-GAAP financial measure. Refer to the "Non-GAAP Financial Measures and Ratios" section of this document for additional details.

2

Base EPS and base return on equity are non-GAAP ratios. Refer to the "Non-GAAP Financial Measures and Ratios" section of this document for additional details.

3

Base return on equity and return on equity are calculated using the trailing four quarters of applicable earnings and common shareholders' equity.

 

Business Highlights

Strategic acquisition of the full-service retirement business of Prudential Financial, Inc. closed

  • On April 1, 2022, a Lifeco subsidiary, Great-West Life & Annuity Insurance Company (GWL&A), which operates primarily as "Empower", closed the previously announced acquisition of the full-service retirement business of Prudential Financial, Inc. (Prudential).  With the close of the acquisition, Empower's reach in the U.S. has expanded to more than 17.4 million retirement plan participants and assets under administration (AUA) to US$1.3 trillion on behalf of approximately 71,000 workplace savings plans as of June 30, 2022.
    The Company funded the total transaction value of US$3,480 million with US$1,193 million of limited recourse capital notes and US$823 million of short-term debt, in addition to existing resources.
    The Prudential acquisition added $116 billion in total on balance sheet assets, $1 billion in other assets under management4 and $250 billion in other assets under administration4 to the U.S. segment as at June 30, 2022.
    On August 1, 2022, Great-West Life & Annuity Insurance Company changed its legal name to Empower Annuity Insurance Company of America.

Capital strength and financial flexibility maintained

  • The Company's capital position remained strong at June 30, 2022, with a LICAT Ratio5 for Canada Life, Lifeco's major Canadian operating subsidiary, of 117% which is near the high end of the Company's internal target range and above the supervisory target. The LICAT Ratio reduced by two points in the quarter mainly due to the material in-quarter increase in interest rates.
  • On July 21, 2022, OSFI released the 2023 LICAT Guideline.  The Company will first report under this guideline in its March 31, 2023 LICAT filing.  Based on an initial review of the guideline under the current market and economic conditions, the Company expects a positive impact to the March 31, 2023 LICAT Ratio6 on transition.

Consolidated assets of $670 billion and assets under administration7 of $2.3 trillion

  • Consolidated assets were approximately $670 billion and AUA were approximately $2.3 trillion as at June 30, 2022, an increase of 6% and 2%, respectively, from December 31, 2021.

Other Developments

  • On June 28, 2022, the Company hosted an analyst discussion on the expected impacts of the upcoming implementation of IFRS 178. The Company does not expect the new standard to have a material financial impact or to change the Company's underlying business strategy9.
  • The Company participated in the International Sustainability Standards Board (ISSB) consultation on two new draft standards which will help facilitate consistent, comparable and timely sustainability information for the good of the capital markets and, more importantly, our planet and our communities.  The Company is a proud supporter of the ISSB as a member of the Coalition of Canadian Champions.

____________________

4

Refer to the "Glossary" section of the Company's second quarter of 2022 interim MD&A for additional details on the composition of other assets under management and other assets under administration.

5

The Life Insurance Capital Adequacy Test (LICAT) Ratio is based on the consolidated results of The Canada Life Assurance Company (Canada Life), Lifeco's major Canadian operating subsidiary. The LICAT Ratio is calculated in accordance with the Office of Superintendent of Financial Institutions (OSFI)' guideline - Life Insurance Capital Adequacy Test. Refer to the "Capital Management and Adequacy" section of the Company's second quarter of 2022 interim MD&A for additional details.

6

Actual impact will depend on market and economic conditions and the Company's operating results at the time of transition.

7

Assets under administration is a non-GAAP financial measure. Refer to the "Non-GAAP Financial Measures and Ratios" section of this document for additional details.

8

IFRS 17, Insurance Contracts (IFRS 17) will replace IFRS 4, Insurance Contracts effective January 1, 2023. The new standard will change the recognition and measurement of insurance contracts and the corresponding presentation and disclosures in the Company's financial statements. 

9

Refer to the "Update on transition to IFRS 17 and IFRS 9" section of the Company's second quarter of 2022 interim MD&A for additional details.

SEGMENTED OPERATING RESULTS

For reporting purposes, Lifeco's consolidated operating results are grouped into five reportable segments – Canada, United States, Europe, Capital and Risk Solutions and Lifeco Corporate – reflecting the management and corporate structure of the Company. For more information, refer to the Company's second quarter of 2022 interim MD&A.

CANADA

  • Q2 Canada segment base earnings of $296 million and net earnings of $301 million – Base earnings for the second quarter of 2022 were $296 million, up 1% compared to the second quarter of 2021. The increase was primarily due to favourable morbidity and investment experience in Group Customer, partially offset by lower fee income and unfavourable experience in Individual Customer. 
  • Canada Life announced 2022 dividend scale for participating life insurance – On May 12, 2022, Canada Life announced the dividend scale interest rate will increase for the policies in the combined open participating account effective July 1, 2022 to 5.25%.
  • Significant joint sale with ClaimSecure Inc. (ClaimSecure) – Canada Life Group Customer and ClaimSecure had their first significant joint sale in the second quarter of 2022.  Integration is going well and quoting momentum is strong. Partnering with ClaimSecure has enhanced Canada Life's ability to provide leading workplace benefits solutions to Canadians.

UNITED STATES

  • Q2 United States (U.S.) Financial Services base earnings of US$123 million ($156 million) and net earnings of US$84 million ($107 million) – U.S. Financial Services base earnings for the second quarter of 2022 were US$123 million ($156 million), down US$16 million or 12% from the second quarter of 2021.  The decrease was primarily due to lower Empower net fee income and higher operating expenses to support participant growth.  These items were partially offset by base earnings of US$35 million ($45 million) related to the Prudential acquisition as well as higher contributions from investment experience.
    Transaction costs of US$42 million ($53 million) related to the Prudential acquisition were included in the U.S. Corporate results.
  • Run-rate cost synergies are on track – Annualized run rate cost synergies of US$88 million pre-tax have been achieved as of June 30, 2022 related to the Company's acquisition of MassMutual's retirement services business compared to US$80 million as of March 31, 2022.  The Company remains on track to achieve run rate cost synergies of US$160 million pre-tax at the end of integration in 2022.
    Empower anticipates realizing cost synergies through the migration of Prudential's retirement services business onto Empower's recordkeeping platform.  Estimated run-rate cost synergies of US$180 million are expected to be phased in over 24 months primarily when systems migrations are completed.  As of June 30, 2022, annualized run rate cost synergies of US$25 million pre-tax have been achieved.
  • Empower growth in AUA and participant accounts – Empower AUA increased to US$1.3 trillion at June 30, 2022 from US$1.1 trillion at December 31, 2021.  Empower participant accounts have grown to 17.4 million at June 30, 2022, up from 13.0 million at December 31, 2021.  The increases in AUA and participants were primarily the result of the Prudential acquisition.
  • Q2 Putnam net loss of US$9 million ($12 million) Putnam's net loss for the second quarter of 2022 was US$9 million ($12 million), compared to net earnings of US$17 million ($21 million) in the second quarter of 2021, primarily due to lower asset based fee revenue and lower net investment income, partially offset by lower expenses.  For Putnam, there were no differences between net and base earnings (loss).
  • Putnam continues to sustain strong investment performance – As of June 30, 2022, approximately 65% and 79% of Putnam's fund assets performed at levels above the Lipper median on a three-year and five-year basis, respectively.  In addition, 42% and 64% of Putnam's fund assets were in the Lipper top quartile on a three-year and five-year basis, respectively.  Putnam has 23 funds currently rated 4 or 5 stars by Morningstar Ratings.
  • Putnam launched new sustainable investment options – During the second quarter of 2022, Putnam made a series of product-related announcements to meet evolving market demand for sustainable investment options, which are expected to launch over the coming months.

EUROPE

  • Q2 Europe segment base earnings of $208 million and net earnings of $229 million – Base earnings for the second quarter of 2022 were $208 million, up 13% compared to the second quarter of 2021, primarily due to favourable investment experience in the U.K, favourable morbidity experience in Ireland as well as favourable mortality experience in the U.K. and Ireland, partially offset by the impact of currency movement.  In addition, the Company had a revaluation of deferred taxes resulting in an increase in taxes in the second quarter of 2021; there was no revaluation in 2022. Net earnings for the second quarter of 2022 were $229 million, up $44 million or 24% from the second quarter of 2021, primarily due to an increase in base earnings as well as favourable market-related impacts driven by property cash flows in the U.K. in 2022 and unfavourable U.K. tax legislation changes in 2021. The increase was partially offset by lower actuarial assumption changes.
  • Strong Insurance and Annuity sales10 – In the second quarter of 2022, Insurance and Annuity sales increased by 21% over the second quarter of 2021.
  • Irish Life invested in a minority shareholding in Multiply.AI (Multiply) – In the second quarter of 2022, Irish Life invested in a minority shareholding in U.K.-based financial technology company Multiply.  Multiply helps clients achieve their financial goals by connecting them through an automated digital advice service to their own individual financial plans with recommended next steps and access to their chosen advisor.  This investment allows Irish Life to build on its existing digital capabilities by designing and building compliant digital customer journeys specific to the Irish market.
  • Canada Life U.K. recognized as leading provider – The recent group protection industry survey 'Group Watch 2022' from Swiss Re confirmed Canada Life U.K. as the leading provider by in-force premium, policies and lives insured.
  • Canada Life's Credit Rating improved in Germany – In the second quarter of 2022, ASSEKURATA Assekuranz Rating-Agentur GmbH, a German financial strength rating agency, raised the credit rating of Canada Life Assurance Europe plc, a subsidiary of Canada Life, from AA- to AA, making Canada Life one of the highest rated life insurance companies in Germany.

_________________

10

Refer to the "Glossary" section of the Company's second quarter of 2022 interim MD&A for additional details on the composition of sales.

 

CAPITAL AND RISK SOLUTIONS

  • Q2 Capital and Risk Solutions segment base earnings of $174 million and net earnings of $167 millionBase earnings for the second quarter of 2022 were $174 million, up 16% compared to the second quarter of 2021, primarily due to growth in business in-force, favourable claims experience in the U.S. life business and the commutation of a reinsurance treaty, partially offset by the impact of currency movement.
  • Continue growing presence in the global reinsurance market – In the second quarter of 2022, Capital and Risk Solutions continued growing its international presence in Asia, Europe and the U.S.  The Company entered into another reinsurance transaction in Israel, completed new longevity contracts in the U.K. and added new structured transactions in the U.S. during the quarter.

QUARTERLY DIVIDENDS

The Board of Directors approved a quarterly dividend of $0.4900 per share on the common shares of Lifeco payable September 29, 2022 to shareholders of record at the close of business September 1, 2022.

In addition, the Directors approved quarterly dividends on Lifeco's first preferred shares payable September 29, 2022 to shareholders of record at the close of business September 1, 2022, as follows:

First Preferred Shares

Amount, per share

Series G

$0.3250

Series H

$0.30313

Series I

$0.28125

Series L

$0.353125

Series M

$0.3625

Series N

$0.109313

Series P

$0.3375

Series Q

$0.321875

Series R

$0.3000

Series S

$0.328125

Series T

$0.321875

Series Y

$0.28125

For purposes of the Income Tax Act (Canada), and any similar provincial legislation, the dividends referred to above are eligible dividends.

Second Quarter Conference Call
Lifeco's second quarter conference call and audio webcast will be held August 4, 2022 at 2:30 p.m. (ET). The call and webcast can be accessed through greatwestlifeco.com/news-events/events or by phone at:

  • Participants in the Toronto area: 416-915-3239
  • Participants from North America: 1-800-319-4610

A replay of the call will be available until September 4, 2022 and can be accessed by calling 1-855-669- 9658 or 604-674-8052 (passcode: 9170). The archived webcast will be available on greatwestlifeco.com.

Selected financial information is attached.

GREAT-WEST LIFECO INC.
Great-West Lifeco is an international financial services holding company with interests in life insurance, health insurance, retirement and investment services, asset management and reinsurance businesses. We operate in Canada, the United States and Europe under the brands Canada Life, Empower, Putnam Investments, and Irish Life. At the end of 2021, our companies had approximately 28,000 employees, 215,000 advisor relationships, and thousands of distribution partners – all serving over 33 million customer relationships across these regions. Great- West Lifeco trades on the Toronto Stock Exchange (TSX) under the ticker symbol GWO and is a member of the Power Corporation group of companies. To learn more, visit greatwestlifeco.com.

Basis of presentation
The condensed consolidated interim unaudited financial statements of Lifeco have been prepared in accordance with International Financial Reporting Standards (IFRS) unless otherwise noted and are the basis for the figures presented in this release, unless otherwise noted.

Cautionary note regarding Forward-Looking Information
This release may contain forward-looking information.  Forward-looking information includes statements that are predictive in nature, depend upon or refer to future events or conditions, or include words such as "will", "may", "expects", "anticipates", "intends", "plans", "believes", "estimates", "objective", "target", "potential" and other similar expressions or negative versions thereof.  These statements include, without limitation, statements about the expected impact (or lack of impact) of IFRS 17, Insurance Contracts and IFRS 9, Financial Instruments on the Company's business strategy, financial strength, deployable capital, Life Insurance Capital Adequacy Test (LICAT) ratio, base and net earnings, shareholders' equity, ratings and leverage ratios.  Forward-looking information also includes statements about the Company's operations, business (including business mix), financial condition, expected financial performance (including revenues, earnings or growth rates), ongoing business strategies or prospects, climate-related goals, anticipated global economic conditions and possible future actions by the Company, including statements made with respect to the expected cost (including deferred consideration), benefits, timing of integration activities and timing and extent of revenue and expense synergies of acquisitions and divestitures, including but not limited to the acquisitions of the full-service retirement business of Prudential Financial Inc. (Prudential), Personal Capital Corporation (Personal Capital) and the retirement services business of Massachusetts Mutual Life Insurance Company (MassMutual), expected capital management activities and use of capital, estimates of risk sensitivities affecting capital adequacy ratios, expected dividend levels, expected cost reductions and savings, expected expenditures or investments (including but not limited to investment in technology infrastructure and digital capabilities and solutions), the timing and completion of the joint venture between Allied Irish Banks plc and Canada Life Irish Holding Company Limited, the impact of regulatory developments on the Company's business strategy and growth objectives, the expected impact of the current pandemic health event resulting from the coronavirus (COVID-19) and related economic and market impacts on the Company's business operations, financial results and financial condition.

Forward-looking statements are based on expectations, forecasts, estimates, predictions, projections and conclusions about future events that were current at the time of the statements and are inherently subject to, among other things, risks, uncertainties and assumptions about the Company, economic factors and the financial services industry generally, including the insurance, mutual fund and retirement solutions industries.  They are not guarantees of future performance, and the reader is cautioned that actual events and results could differ materially from those expressed or implied by forward-looking statements.  Many of these assumptions are based on factors and events that are not within the control of the Company and there is no assurance that they will prove to be correct.  In particular, statements about the expected impact of IFRS 17 on the Company (including statements about the impact on base and net earnings and the Canada Life Assurance Company LICAT Ratio) are based on the Company's expected 2022 IFRS 4 earnings mix and composition as at the start of 2022, adjusted to reflect fully synergized earnings from the acquisitions of MassMutual's and Prudential's retirement businesses, and on current market and economic conditions.  In all cases, whether or not actual results differ from forward-looking information may depend on numerous factors, developments and assumptions, including, without limitation, the severity, magnitude and impact of the COVID-19 pandemic including the effects of the COVID-19 pandemic and the effects of governments' and other businesses' responses to the COVID-19 pandemic on the economy and the Company's financial results, financial condition and operations), the duration of COVID-19 impacts and the availability and adoption of vaccines, the effectiveness of vaccines, the emergence of COVID-19 variants, geopolitical tensions and related economic impacts, assumptions around sales, fee rates, asset breakdowns, lapses, plan contributions, redemptions and market returns, the ability to integrate the acquisitions of Personal Capital and the retirement services business of MassMutual and Prudential, the ability to leverage Empower's, Personal Capital's and MassMutual's and Prudential's retirement services businesses and achieve anticipated synergies, customer behaviour (including customer response to new products), the Company's reputation, market prices for products provided, sales levels, premium income, fee income, expense levels, mortality experience, morbidity experience, policy and plan lapse rates, participant net contribution, reinsurance arrangements, liquidity requirements, capital requirements, credit ratings, taxes, inflation, interest and foreign exchange rates, investment values, hedging activities, global equity and capital markets (including continued access to equity and debt markets), industry sector and individual debt issuers' financial conditions (including developments and volatility arising from the COVID-19 pandemic, particularly in certain industries that may comprise part of the Company's investment portfolio), business competition, impairments of goodwill and other intangible assets, the Company's ability to execute strategic plans and changes to strategic plans, technological changes, breaches or failure of information systems and security (including cyber attacks), payments required under investment products, changes in local and international laws and regulations, changes in accounting policies and the effect of applying future accounting policy changes, changes in actuarial standards, unexpected judicial or regulatory proceedings, catastrophic events, continuity and availability of personnel and third party service providers, the Company's ability to complete strategic transactions and integrate acquisitions, unplanned material changes to the Company's facilities, customer and employee relations or credit arrangements, levels of administrative and operational efficiencies, changes in trade organizations, and other general economic, political and market factors in North America and internationally.  In addition, as we work to advance our climate goals, external factors outside of Lifeco's reasonable control may act as constraints on their achievement, including varying decarbonization efforts across economies, the need for thoughtful climate policies around the world, more and better data, reasonably supported methodologies, technological advancements, the evolution of consumer behavior, the challenges of balancing interim emissions goals with an orderly and just transition, and other significant considerations such as legal and regulatory obligations. 

The reader is cautioned that the foregoing list of assumptions and factors is not exhaustive, and there may be other factors listed in other filings with securities regulators, including factors set out in the Company's 2021 Annual MD&A under "Risk Management and Control Practices" and "Summary of Critical Accounting Estimates" and in the Company's annual information form dated February 9, 2022 under "Risk Factors", which, along with other filings, is available for review at www.sedar.com. The reader is also cautioned to consider these and other factors, uncertainties and potential events carefully and not to place undue reliance on forward-looking information. 

Other than as specifically required by applicable law, the Company does not intend to update any forward-looking information whether as a result of new information, future events or otherwise.

Cautionary note regarding Non-GAAP Financial Measures and Ratios

This release contains some non-Generally Accepted Accounting Principles (GAAP) financial measures and non-GAAP ratios as defined in National Instrument 52-112 "Non-GAAP and Other Financial Measures Disclosure". Terms by which non-GAAP financial measures are identified include, but are not limited to, "base earnings (loss)", "base earnings (loss) (US$)" and "assets under administration". Terms by which non-GAAP ratios are identified include, but are not limited to, "base earnings per common share (EPS)", and "base return on equity (ROE)". Non-GAAP financial measures and ratios are used to provide management and investors with additional measures of performance to help assess results where no comparable GAAP (IFRS) measure exists. However, non-GAAP financial measures and ratios do not have standard meanings prescribed by GAAP (IFRS) and are not directly comparable to similar measures used by other companies. Refer to the "Non-GAAP Financial Measures and Ratios" section in this release for the appropriate reconciliations of these non-GAAP financial measures to measures prescribed by GAAP as well as additional details on each measure and ratio.

FINANCIAL HIGHLIGHTS (unaudited)
(in Canadian $ millions, except per share amounts)



As at or for the three months ended



 

For the six months ended




June 30
2022


March 31
2022


June 30 
2021



June 30

2022


June 30

2021


Earnings













Base earnings1

$

830

$

809

$

826


$

1,639

$

1,565


Net earnings - common shareholders


735


770


784



1,505


1,491


Per common share













Basic:













Base earnings2


0.893


0.869


0.889



1.762


1.685


Net earnings


0.789


0.827


0.844



1.616


1.605


Diluted net earnings


0.788


0.825


0.842



1.613


1.604


Dividends paid


0.490


0.490


0.438



0.980


0.876


Book value3


25.00


24.57


23.70




















Base return on equity2


14.5 %


14.7 %


13.9 %







Return on equity3


13.7 %


14.1 %


15.0 %







Total net premiums

$

16,305

$

14,051

$

11,751


$

30,356

$

24,903


Total premiums and deposits1


41,591


44,158


36,804



85,749


81,867


Fee and other income


1,909


1,813


1,800



3,722


3,551















Net policyholder benefits, dividends and
     experience refunds


15,030


12,747


12,162



27,777


24,096


Total assets per financial statements

$

670,305

$

600,459

$

604,176







Total assets under management1


988,986


954,395


962,473







Total assets under administration1,4


2,342,296


2,187,706


2,167,107




















Total equity

$

30,550

$

30,387

$

27,956




















The Canada Life Assurance Company
     consolidated LICAT Ratio5


117 %


119 %


126 %




















1 

This metric is a non-GAAP financial measure.  Refer to the "Non-GAAP Financial Measures and Ratios" section of this document for additional details.

2 

This metric is a non-GAAP ratio.  Refer to the "Non-GAAP Financial Measures and Ratios" section of this document for additional details.

3 

Refer to the "Glossary" section of the Company's second quarter of 2022 interim MD&A for additional details on the composition of this measure.

4 

2021 comparative figures have been restated to include Financial Horizons Group and Excel Private Wealth Inc. assets under administration in the Canada segment.

5 

The Life Insurance Capital Adequacy Test (LICAT) Ratio is based on the consolidated results of The Canada Life Assurance Company (Canada Life), Lifeco's major Canadian operating subsidiary.  The LICAT Ratio is calculated in accordance with the Office of Superintendent of Financial Institutions' guideline - Life Insurance Capital Adequacy Test.  Refer to the "Capital Management and Adequacy" section of the Company's second quarter of 2022 interim MD&A for additional details.

 

BASE AND NET EARNINGS

Base earnings1 and net earnings - common shareholders (Unaudited)















For the three months ended



For the six months ended




June 30

2022


March 31
2022


June 30 
2021



June 30

2022


June 30 
2021


Base earnings1













Canada

$

296

$

272

$

293


$

568

$

591


United States


143


120


190



263


294


Europe


208


245


184



453


385


Capital and Risk Solutions


174


170


150



344


295


Lifeco Corporate


9


2


9



11



Lifeco base earnings1

$

830

$

809

$

826


$

1,639

$

1,565















Items excluded from base earnings













Actuarial assumption changes and other management actions2

$

21

$

(9)

$

37


$

12

$

42


Market-related impacts on liabilities2


(15)


(11)


(19)



(26)


(43)


Transaction costs related to acquisitions3


(57)


(7)


(24)



(64)


(25)


Restructuring and integration costs


(44)


(12)


(15)



(56)


(27)


Tax legislative changes impact on liabilities




(21)




(21)


Items excluded from Lifeco base earnings

$

(95)

$

(39)

$

(42)


$

(134)

$

(74)


Net earnings - common shareholders













Canada

$

301

$

275

$

288


$

576

$

575


United States


29


105


150



134


239


Europe


229


219


185



448


380


Capital and Risk Solutions


167


169


152



336


297


Lifeco Corporate


9


2


9



11



Lifeco net earnings - common shareholders

$

735

$

770

$

784


$

1,505

$

1,491



1 

This metric is a non-GAAP financial measure.  Refer to the "Non-GAAP Financial Measures and Ratios" section of this document for additional details.

2 

Refer to the "Glossary" section of the Company's second quarter of 2022 interim MD&A for additional details on the composition of this measure.

3 

The transaction costs relate to acquisitions in the U.S. segment (the full-service retirement business of Prudential, Personal Capital and the retirement services business of MassMutual) as well as acquisitions in the Europe segment.

 

NON-GAAP FINANCIAL MEASURES AND RATIOS

Non-GAAP Financial Measures
The Company uses several non-GAAP financial measures to measure overall performance of the Company and to assess each of its business units.  A financial measure is considered a non-GAAP measure for Canadian securities law purposes if it is presented other than in accordance with GAAP used for the Company's consolidated financial statements.  The consolidated financial statements of the Company have been prepared in compliance with IFRS as issued by the International Accounting Standards Board (IASB).  Non-GAAP financial measures do not have a standardized meaning under GAAP and may not be comparable to similar financial measures presented by other issuers.  Investors may find these financial measures useful in understanding how management views the underlying business performance of the Company.

Base earnings (loss)
Base earnings (loss) reflect management's view of the underlying business performance of the Company and provide an alternate measure to understand the underlying business performance compared to IFRS net earnings (loss).  Base earnings (loss) exclude the following items:

  • The impact of actuarial assumption changes and other management actions;
  • The net earnings impact related to the direct equity and interest rate market impacts on insurance and investment contract liabilities, net of hedging, and related deferred tax liabilities, which includes:
    • the impact of hedge ineffectiveness related to segregated fund guarantee liabilities that are hedged and the performance of the related hedge assets;
    • the impact on segregated fund guarantee liabilities not hedged;
    • the impact on general fund equity and investment properties supporting insurance contract liabilities;
    • other market impacts on insurance and investment contract liabilities and deferred tax liabilities, including those arising from the difference between actual and expected market movements; and
  • Certain items that, when removed, assist in explaining the Company's underlying business performance including restructuring costs, integration costs related to business acquisitions, material legal settlements, material impairment charges related to goodwill and intangible assets, impact of substantially enacted income tax rate changes and other tax impairments and net gains, losses or costs related to the disposition or acquisition of a business.

Lifeco1














For the three months ended



For the six months ended



June 30

2022


March 31

2022


June 30

2021



June 30

2022


June 30

2021

Base earnings

$

830

$

809

$

826


$

1,639

$

1,565













Items excluded from Lifeco base earnings












Actuarial assumption changes and other

  management actions (pre-tax)

$

24

$

(9)

$

42


$

15

$

46

Income tax (expense) benefit


(3)



(5)



(3)


(4)

Market-related impacts on liabilities (pre-tax)


(19)


(14)


(14)



(33)


(39)

Income tax (expense) benefit


4


3


(5)



7


(4)

Transaction costs related to acquisitions (pre-tax)


(71)


(8)


(25)



(79)


(27)

Income tax (expense) benefit


14


1


1



15


2

Restructuring and integration costs (pre-tax)


(60)


(17)


(21)



(77)


(37)

Income tax (expense) benefit


16


5


6



21


10

Tax legislative changes impact on liabilities




(21)




(21)

Total pre-tax items excluded from base earnings

$

(126)

$

(48)

$

(18)


$

(174)

$

(57)

Impact of items excluded from base

   earnings on income taxes


31


9


(24)



40


(17)

Net earnings - common shareholders

$

735

$

770

$

784


$

1,505

$

1,491













1  

There is no difference between base earnings and net earnings for Lifeco Corporate in the periods presented.

 

Canada















For the three months ended



For the six months ended




June 30

2022


March 31

2022


June 30

2021



June 30

2022


June 30

2021


Base earnings

$

296

$

272

$

293


$

568

$

591















Items excluded from base earnings













Actuarial assumption changes and other

  management actions (pre-tax)

$

1

$

1

$

(7)


$

2

$

(25)


Income tax (expense) benefit



(1)


1



(1)


6


Market-related impacts on liabilities (pre-tax)


6


4


1



10


3


Income tax (expense) benefit


(2)


(1)




(3)



Net earnings - common shareholders

$

301

$

275

$

288


$

576

$

575


 

United States















For the three months ended



For the six months ended




June 30

2022


March 31

2022


June 30

2021



June 30

2022


June 30

2021


Base earnings

$

143

$

120

$

190


$

263

$

294















Items excluded from base earnings













Market-related impacts on liabilities (pre-tax)

$

(21)

$

(3)

$

(1)


$

(24)

$

(3)


Income tax (expense) benefit


4


1




5



Restructuring and integration costs (pre-tax)


(60)


(17)


(21)



(77)


(37)


Income tax (expense) benefit


16


5


6



21


10


Transaction costs related to acquisitions (pre-tax)


(67)


(2)


(25)



(69)


(27)


Income tax (expense) benefit


14


1


1



15


2


Net earnings - common shareholders

$

29

$

105

$

150


$

134

$

239


 

Europe















For the three months ended



For the six months ended




June 30

2022


March 31

2022


June 30

2021



June 30

2022


June 30

2021


Base earnings

$

208

$

245

$

184


$

453


385















Items excluded from base earnings













Actuarial assumption changes and other

  management actions (pre-tax)

$

22

$

(9)

$

48


$

13

$

70


Income tax (expense) benefit


(3)


1


(7)



(2)


(11)


Market-related impacts on liabilities (pre-tax)


4


(15)


(14)



(11)


(39)


Income tax (expense) benefit


2


3


(5)



5


(4)


Transaction costs related to acquisitions (pre-tax)


(4)


(6)




(10)



Income tax (expense) benefit








Tax legislative changes impact on liabilities




(21)




(21)


Net earnings - common shareholders

$

229

$

219

$

185


$

448

$

380


 

Capital and Risk Solutions














For the three months ended


For the six months ended




June 30

2022


March 31

2022


June 30

2021



June 30

2022


June 30

2021


Base earnings

$

174

$

170

$

150


$

344

$

295















Items excluded from base earnings













Actuarial assumption changes and other

  management actions (pre-tax)

$

1

$

(1)

$

1


$

$

1


Income tax (expense) benefit




1




1


Market-related impact on liabilities (pre-tax)


(8)





(8)



Income tax (expense) benefit








Net earnings - common shareholder

$

167

$

169

$

152



336

$

297


 

Premiums and deposits
Total premiums and deposits include premiums on risk-based insurance and annuity products net of ceded reinsurance (as defined under IFRS as net premium income), premium equivalents on self-funded group insurance administrative services only (ASO) contracts, deposits on individual and group segregated fund products as well as deposits on proprietary mutual funds and institutional accounts.  This measure provides an indicator of top-line growth.

Premiums and deposits















For the three months ended



For the six months ended




June 30

2022


March 31

2022


June 30

2021



June 30

2022


June 30

2021


Total net premiums

$

16,305

$

14,051

$

11,751


$

30,356

$

24,903


Policyholder deposits (segregated funds)1


6,847


8,273


6,634



15,120


14,587















Self-funded premium equivalents (ASO contracts)
  and other


2,739


2,893


2,021



5,632


3,724















Proprietary mutual funds and institutional deposits


15,700


18,941


16,398



34,641


38,653


Total premiums and deposits1

$

41,591

$

44,158

$

36,804


$

85,749

$

81,867















1

Refer to note 9(b) of the Company's condensed interim unaudited financial statements for the period ended June 30, 2022 for further details.

 

Assets under management (AUM) and assets under administration (AUA)
Assets under management and assets under administration are non-GAAP measures that provide an indicator of the size and volume of the Company's overall business.  Administrative services are an important aspect of the overall business of the Company and should be considered when comparing volumes, size and trends.

Total assets under administration includes total assets per financial statements, other assets under management and other assets under administration.

Assets under administration












As at




June 30

2022


March 31

2022


Dec. 31
2021


June 30

2021


Total assets per financial statements

$

670,305

$

600,459

$

630,488

$

604,176


  Other AUM


318,681


353,936


377,155


358,297


Total AUM


988,986


954,395


1,007,643


962,473


  Other AUA1


1,353,310


1,233,311


1,283,949


1,204,634


Total AUA1

$

2,342,296

$

2,187,706

$

2,291,592

$

2,167,107












1

2021 comparative figures have been restated to include Financial Horizons Group and Excel Private Wealth Inc. assets under administration in the Canada segment.

 

Non-GAAP Ratios 
A non-GAAP ratio is a financial measure in the form of a ratio, fraction, percentage or similar representation that is not disclosed in the consolidated financial statements of the Company and has a non-GAAP financial measure as one or more of its components.  These financial measures do not have a standardized definition under GAAP and might not be comparable to similar financial measures presented by other issuers.

The non-GAAP ratios disclosed by the Company each use base earnings (loss) as the non-GAAP component.  Base earnings (loss) reflect management's view of the underlying business performance of the Company and provide an alternate measure to understand the underlying business performance compared to IFRS net earnings.

  • Base earnings per share - Base earnings (loss) for the period is divided by the number of average common shares outstanding for the period.
  • Base return on equity - Base earnings (loss) for the trailing four quarters are divided by the average common shareholders' equity over the trailing four quarters. This measure provides an indicator of business unit profitability.

 

SOURCE Great-West Lifeco Inc.

Read More

Continue Reading

International

John Lewis relies too heavily on its heritage – here’s what it could do instead

The company has returned to profit by making cuts, but there are things it could do to reinvent itself.

Published

on

By

Road to recovery? Jevanto Productions/Shutterstock

In a tricky economic climate, the British department store John Lewis has managed to deliver some good news. The retail partnership – owned by its 80,000 employees – posted pre-tax profits of £56 million after a £234 million loss the year before.

The positive announcement was somewhat tarnished by the fact that those employees (known as partners) would not receive a bonus for the second year in a row. There were also hints of job cuts.

But what more could this giant of UK retail, which also owns Waitrose supermarkets, do to endure its survival? Does its increasing reliance on grocery sales mean its own brand has become less valuable?

For over 160 years on the high street, John Lewis has worked hard on that brand. Its slogan (scrapped in 2022) about being “never knowingly undersold” was well known, it remains a trusted supplier of an extensive range of household hoods, rates highly for customer service, and runs Christmas TV adverts which have became a media event in themselves.

In doing all of those things, John Lewis seemed to be in a much better place than its rivals. BHS (founded in 1928) and Debenhams (1778) have disappeared from the high street. House of Fraser (1849) was taken over and has a much-reduced physical presence.

John Lewis’s nearest rival, Marks & Spencer (1884), is now doing well, but only after it underwent a fairly brutal restructuring which involved cutting thousands of jobs during the pandemic, closing 67 stores, and slashing its operations in France.

So John Lewis’s “brand heritage” – its history, tradition and pedigree – has worked pretty well for a pretty long time. But its recent return to profit was the combined effort of reinvesting and streamlining, according to some reports.

Also known as “trimming the fat” in the business world, the retailer’s streamlining endeavours consisted of cutting more than 1,500 jobs, and closing underperforming stores, such as the branch in Sheffield, which had served residents for nearly 80 years and was much mourned, including by my own mother-in-law.

It has also been reported that more job cuts are imminent, with up to 11,000 jobs to go in the next five years.

And perhaps these measures highlight some of the harsh realities of running a department store in the always-open and effortless world of online shopping. Maybe employees (even those considered partners, as under John Lewis’s employee-ownership model) have become expendable.

Maybe physical stores, where consumers go to explore and seek advice, have become expendable. Maybe all traditions are expendable when they are not commercially viable.

People first

Yet the world of retail is filled with examples of heritage brands reinventing themselves to stay relevant, buoyant and competitive.

John Lewis will need to do the same if it wants to retain its legacy on the British high street. And it could do worse than taking a leaf out of Waitrose’s playbook.

For the company’s return to profit was largely due to the buoyant sales generated by Waitrose supermarkets, which increased by 4%. The department store business meanwhile, suffered a 2% fall.

Part of Waitrose’s success comes from providing a sense of indulgence and enjoyment – including healthy food – through carefully curated and often locally sourced products. It works closely with local farmers, supports regional suppliers (an approach that has also contributed to M&S’s success), and reinvests in stores and product offers.

Essentially, as part of UK’s grocery sector, Waitrose extended its partnership ethos to include people and groups beyond the shop walls – to build a “local retail ecosystem” that promotes and leverages a community spirit around their stores.

M&S shop front.
Appealing to appetites. Simon Vayro/Shutterstock

John Lewis department stores could try and do something similar. They could focus more on products that help customers live healthier and more active lives, and which are relevant to their interests. They could sell products created by local small businesses, and make a determined approach to be a supportive presence in the regions they serve.

Research suggests that heritage brands benefit from having a moral standing – when they show they care about the people they make money from, the local communities they operate in, and the people they employ.

So perhaps John Lewis should make moral values a part of its evolving heritage. It needs to show it cares not just for the people who work for the company directly, but also the people on whom it relies for success – the customers – and people it can build new relationships with. All of them could prove critical to its future success.

Kokho Jason Sit is affiliated with the Chartered Institute of Marketing.

Read More

Continue Reading

Uncategorized

ARPA-H appoints Etta Pisano to lead its Advancing Clinical Trials Readiness Initiative

The Advanced Research Projects Agency for Health (ARPA-H) has appointed Etta D. Pisano, MD, FACR, senior portfolio lead, to build the agency’s clinical…

Published

on

The Advanced Research Projects Agency for Health (ARPA-H) has appointed Etta D. Pisano, MD, FACR, senior portfolio lead, to build the agency’s clinical trial portfolio and lead the ARPA-H Advancing Clinical Trials Readiness Initiative under ARPA-H Resilient Systems Mission Office Director Jennifer Roberts.

Credit: N/A

The Advanced Research Projects Agency for Health (ARPA-H) has appointed Etta D. Pisano, MD, FACR, senior portfolio lead, to build the agency’s clinical trial portfolio and lead the ARPA-H Advancing Clinical Trials Readiness Initiative under ARPA-H Resilient Systems Mission Office Director Jennifer Roberts.

The first radiologist to be appointed to such a role, Dr. Pisano is an internationally recognized expert in women’s health, breast cancer research, and the use of artificial intelligence in medical imaging applications.

“I am honored to be working for ARPA-H to identify and promote research that can improve healthcare quality, efficacy and delivery, and to improve patient care and access to clinical trials for all Americans, including women, rural residents, and the underserved,” said Dr. Pisano.

Dr. Pisano will continue to serve as study chair of the large-scale Tomosynthesis Mammographic Imaging Screening Trial (TMIST) for the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). TMIST is led by ECOG-ACRIN with funding from the National Cancer Institute, part of the National Institutes of Health. She will also continue to serve as the American College of Radiology® (ACR®) Chief Research Officer (CRO). Dr. Pisano previously served as the principal investigator of the landmark Digital Mammographic Imaging Screening Trial (DMIST).

The TMIST breast cancer screening study is among the fastest growing National Cancer Institute (NCI) trials of the COVID-19 era. Under Dr. Pisano’s leadership, TMIST is assembling one of the most diverse cancer screening trial populations ever. Approximately 21% of TMIST U.S. participants are Black—more than double the average rate for Black participation in NCI-funded clinical trials (9%).

With ARPA-H, Dr. Pisano will work to build underserved and minority participation in clinical trials—including identifying and onboarding rural facilities and those outside of large academic medical centers—such as emerging retail healthcare sites. 

These duties are also very consistent with the missions of ECOG-ACRIN and ACR, which include promoting the exploration and identification of next-generation technologies that can benefit patients and providers.

“This is a great opportunity for Etta, and I’m excited about the impact she will make on our approach to clinical trials,” said Mitchell D. Schnall, MD, PhD, group co-chair of ECOG-ACRIN.

About ECOG-ACRIN

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) is an expansive membership-based scientific organization that designs and conducts cancer research involving adults who have or are at risk of developing cancer. The Group comprises nearly 1400 member institutions and 21,000 research professionals in the United States and around the world. ECOG-ACRIN is known for advancing precision medicine and biomarker research through its leadership of major national clinical trials integrating cutting-edge genomic approaches. Member researchers and advocates collaborate across more than 40 scientific committees to design studies spanning the cancer care spectrum, from early detection to management of advanced disease. ECOG-ACRIN is funded primarily by the National Cancer Institute, part of the National Institutes of Health. Visit ecog-acrin.org, and follow us on X @eaonc, Facebook, LinkedIn, and Instagram.

Media Contact: Diane Dragaud, Director of Communications, communications@ecog-acrin.org.


Read More

Continue Reading

Spread & Containment

Bacteria subtype linked to growth in up to 50% of human colorectal cancers, Fred Hutch researchers report

Researchers at Fred Hutchinson Cancer Center have found that a specific subtype of a microbe commonly found in the mouth is able to travel to the gut and…

Published

on

Researchers at Fred Hutchinson Cancer Center have found that a specific subtype of a microbe commonly found in the mouth is able to travel to the gut and grow within colorectal cancer tumors. This microbe is also a culprit for driving cancer progression and leads to poorer patient outcomes after cancer treatment.

Credit: Fred Hutchinson Cancer Center

Researchers at Fred Hutchinson Cancer Center have found that a specific subtype of a microbe commonly found in the mouth is able to travel to the gut and grow within colorectal cancer tumors. This microbe is also a culprit for driving cancer progression and leads to poorer patient outcomes after cancer treatment.

The findings, published March 20 in the journal Nature, could help improve therapeutic approaches and early screening methods for colorectal cancer, which is the second most common cause of cancer deaths in adults in the U.S. according to the American Cancer Society.

Examining colorectal cancer tumors removed from 200 patients, the Fred Hutch team measured levels of Fusobacterium nucleatum, a bacterium known to infect tumors. In about 50% of the cases, they found that only a specific subtype of the bacterium was elevated in the tumor tissue compared to healthy tissue.

The researchers also found this microbe in higher numbers within stool samples of colorectal cancer patients compared with stool samples from healthy people.

“We’ve consistently seen that patients with colorectal tumors containing Fusobacterium nucleatum have poor survival and poorer prognosis compared with patients without the microbe,” explained Susan Bullman, Ph.D., Fred Hutch cancer microbiome researcher and co-corresponding study author. “Now we’re finding that a specific subtype of this microbe is responsible for tumor growth. It suggests therapeutics and screening that target this subgroup within the microbiota would help people who are at a higher risk for more aggressive colorectal cancer.”

In the study, Bullman and co-corresponding author Christopher D. Johnston, Ph.D., Fred Hutch molecular microbiologist, along with the study’s first author Martha Zepeda-Rivera, Ph.D., a Washington Research Foundation Fellow and Staff Scientist in the Johnston Lab, wanted to discover how the microbe moves from its typical environment of the mouth to a distant site in the lower gut and how it contributes to cancer growth.

First they found a surprise that could be important for future treatments. The predominant group of Fusobacterium nucleatum in colorectal cancer tumors, thought to be a single subspecies, is actually composed of two distinct lineages known as “clades.”

“This discovery was similar to stumbling upon the Rosetta Stone in terms of genetics,” Johnston explained. “We have bacterial strains that are so phylogenetically close that we thought of them as the same thing, but now we see an enormous difference between their relative abundance in tumors versus the oral cavity.”

By separating out the genetic differences between these clades, the researchers found that the tumor-infiltrating Fna C2 type had acquired distinct genetic traits suggesting it could travel from the mouth through the stomach, withstand stomach acid and then grow in the lower gastrointestinal tract. The analysis revealed 195 genetic differences between the clades.

Then, comparing tumor tissue with healthy tissue from patients with colorectal cancer, the researchers found that only the subtype Fna C2 is significantly enriched in colorectal tumor tissue and is responsible for colorectal cancer growth.

Further molecular analyses of two patient cohorts, including over 200 colorectal tumors, revealed the presence of this Fna C2 lineage in approximately 50% of cases.

The researchers also found in hundreds of stool samples from people with and without colorectal cancer that Fna C2 levels were consistently higher in colorectal cancer.

“We  have pinpointed the exact bacterial lineage that is associated with colorectal cancer, and that knowledge is critical for developing effective preventive and treatment methods,” Johnston said.

He and Bullman believe their study presents significant opportunities for developing microbial cellular therapies, which use modified versions of bacterial strains to deliver treatments directly into tumors.

###

Fred Hutchinson Cancer Center unites individualized care and advanced research to provide the latest cancer treatment options while accelerating discoveries that prevent, treat and cure cancer and infectious diseases worldwide.

Based in Seattle, Fred Hutch is an independent, nonprofit organization and the only National Cancer Institute-designated cancer center in Washington. We have earned a global reputation for our track record of discoveries in cancer, infectious disease and basic research, including important advances in bone marrow transplantation, immunotherapy, HIV/AIDS prevention and COVID-19 vaccines. Fred Hutch operates eight clinical care sites that provide medical oncology, infusion, radiation, proton therapy and related services. Fred Hutch also serves as UW Medicine’s cancer program.


Read More

Continue Reading

Trending